Browse by author
Lookup NU author(s): Dr Nigel Cooper,
Dr Geoff Lawson,
Dr Philip Shackley,
Dr Jing Shen,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background: Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes. Methods: SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. Findings: For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0·78 [95% CI 0·63-0·97]), gabapentin (0·65 [0·52-0·80]), and topiramate (0·64 [0·52-0·79]), and had a non-significant advantage compared with oxcarbazepine (1·15 [0·86-1·54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0·75 [0·63-0·90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0·91 [0·77-1·09]), topiramate (0·86 [0·72-1·03]), and oxcarbazepine (0·92 [0·73-1·18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine. Interpretation: Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures. © 2007 Elsevier Ltd. All rights reserved.
Author(s): Shen J; Shackley P; Cooper PN; Doughty J; Vanoli A; Lawson GR; Marson AG; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Al-Kharusi AM; Leach JP; Nicolaides P; Roberts R; Smith DF; Smith PE; Smith CT; Williamson PR; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC
Publication type: Article
Publication status: Published
ISSN (print): 0140-6736
ISSN (electronic): 1474-547X
Publisher: The Lancet Publishing Group
Altmetrics provided by Altmetric